Cinven Completes Amdipharm Acquisition

European private equity firm, Cinven has completed the acquisition of Amdipharm, a family-owned international niche pharmaceuticals business, for a total consideration of 367 million pounds ($593.3 million). This follows Cinven’s acquisition of Mercury Pharma, an international specialty pharmaceuticals company, in August 2012. Amdipharm will be merged, over time, with Mercury Pharma.

PRESS RELEASE

European private equity firm, Cinven, today announces completion of its acquisition of
Amdipharm, the family-owned international niche pharmaceuticals business, for a total
consideration of 367 million pounds ($593.3 million). This follows Cinven’s acquisition of Mercury Pharma, an
international specialty pharmaceuticals company, in August 2012.
Amdipharm will be merged, over time, with Cinven’s existing portfolio company, Mercury
Pharma. The combined group has an enterprise value in excess of £830 million, with
revenues approaching £250 million and a portfolio of more than 200 drugs.
Cinven originated these investments through its healthcare sector focus. Its strategy is to
grow a global niche pharmaceuticals business, both organically and through further
acquisition opportunities, including in emerging markets, and to build on the existing scale
of the combined business.
– Ends –
For further information:
Vanessa Maydon
Cinven
Tel.: + 44 (0) 20 7661 3325 / + 44 (0) 7802 961 902
vanessa.maydon@cinven.com
Marc Cohen (PR Adviser to Cinven)
FTI Consulting
Tel.: + 44 (0) 20 7269 7216
marc.cohen@fticonsulting.com
Cinven Partners LLP
Warwick Court
Paternoster Square
London EC4M 7AG
Tel +44 (0)20 7661 3333
Fax +44 (0)20 7661 3888
www.cinven.com
Registered in England No. OC366256 Cinven Partners LLP is authorised and regulated by the Financial Services Authority Page 2 of 3
Notes to Editors
About Cinven
· Cinven is a leading European private equity firm focused on building world-class
European companies.
· Established in 1977, the firm invests in six key sectors: Business Services, Financial
Services, Healthcare, Industrials, Consumer, and Technology, Media and
Telecommunications (TMT).
· Cinven funds acquire European-based companies that require an equity investment
of €100 million or more.
· Our European focus and expertise are complemented by an ability to capitalise on
global growth opportunities through our Asian office.
· Cinven’s recent investments across all sectors include Mercury Pharma (healthcare)
Pronet (business services), Prezioso (business services), Guardian (financial
services) and CPA Global (business services).
· Cinven has a strong track record in the healthcare sector. Its current portfolio
comprises:
– Mercury Pharma, speciality pharmaceuticals
– Partnerships in Care, secure psychiatric hospital operator
– Sebia, in-vitro diagnostics (protein testing)
– Spire Healthcare, hospital operator
· To date, Cinven has made 13 investments in the healthcare sector (excluding
Amdipharm) representing approximately €[2.75] billion of invested capital and
generating returns of 3.1x on exited investments.
· Cinven has offices in Guernsey, London, Paris, Frankfurt, Milan, Luxembourg and
Hong Kong. Cinven Partners LLP is authorised and regulated by the FSA.
· Cinven acquires successful high quality companies. Using proven value creation
strategies, we work closely with these companies, helping them to grow and develop.
Cinven takes a responsible approach towards its portfolio companies, their
employees, suppliers, local communities, the environment and society.
About Amdipharm
· Amdipharm was formed in 2002 by Vijay and Bhikhu Patel who have enjoyed
business success since the mid-1980s through the operations of Waymade
Healthcare.
· The aim of Amdipharm has been to make essential prescription medicines, which may
no longer be a priority for research-based pharmaceutical companies, available to
patients.
· Through 18 significant acquisitions, Amdipharm has built up a portfolio of more than
50 products which sell in over 80 countries across the world
Cinven Partners LLP
Warwick Court
Paternoster Square
London EC4M 7AG
Tel +44 (0)20 7661 3333
Fax +44 (0)20 7661 3888
www.cinven.com
Registered in England No. OC366256 Cinven Partners LLP is authorised and regulated by the Financial Services Authority Page 3 of 3
· Amdipharm has offices in Jersey, Ireland, the Netherlands, and in the UK at Basildon,
Essex.